Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac N : , GlaxoSmithKline Report Positive Preclinical Data on COVID-19 Vaccine Candidate

05/13/2021 | 08:23am EDT


© MT Newswires 2021
All news about CUREVAC N.V.
06/21European Shares Recover from Friday Declines As Investors Focus on M&A
MT
06/21EUROPE : European stocks end higher as Lagarde talks up economic growth
RE
06/21MARKET CHATTER : German Financial Watchdog to Investigate Possible Insider Tradi..
MT
06/21Germany's BaFin looking into possible insider trading of CureVac shares
RE
06/18EUROPEAN MIDDAY BRIEFING  : Stocks Slip as -2-
DJ
06/18CureVac COVID-19 Jab's Low Efficacy Said To Be Caused By Vaccine's Low Dosage
MT
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
MT
06/17NEWS HIGHLIGHTS  : Top Company News of the Day
DJ
06/17AFTER HOURS WATCH LIST SCORECARD : Stsa, novn, cvac
MT
06/17Health Care Up As Traders Rotate Out Of Rate-Sensitive Sectors -- Health Care..
DJ
More news
Financials
Sales 2021 486 M 580 M 580 M
Net income 2021 341 M 407 M 407 M
Net cash 2021 2 745 M 3 278 M 3 278 M
P/E ratio 2021 17,9x
Yield 2021 -
Capitalization 18 051 M 21 497 M 21 553 M
EV / Sales 2021 31,5x
EV / Sales 2022 3,16x
Nbr of Employees 505
Free-Float 44,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 50,10 €
Average target price 60,18 €
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
NameTitle
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CUREVAC N.V.-26.40%21 497
MODERNA, INC.99.33%83 614
LONZA GROUP AG13.26%52 103
IQVIA HOLDINGS INC.35.88%46 660
CELLTRION, INC.-24.79%33 793
SEAGEN INC.-9.62%28 728